Welcome to our dedicated page for DAXOR SEC filings (Ticker: DXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Daxor Corporation (NASDAQ: DXR) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as a public issuer. Daxor is a medical instrumentation and biotechnology company focused on blood volume measurement, and its filings offer detail on corporate events, governance and the development of its Blood Volume Analysis (BVA) technology.
Through current reports such as Form 8-K, Daxor discloses material events, including FDA 510(k) clearance for its next-generation rapid, portable, lab-based Blood Volume Analyzer (Daxor BVA™) and outcomes of shareholder meetings, such as director elections and auditor ratification. These documents also restate the company’s description as a developer and marketer of the BVA-100 Blood Volume Analyzer, the first FDA-cleared diagnostic blood test to objectively quantify blood volume status and composition compared to patient-specific norms.
On Stock Titan, users can review Daxor’s SEC filings alongside AI-powered summaries that explain the significance of each document in clear language. This includes annual and quarterly reports when filed (Forms 10-K and 10-Q), which typically discuss the company’s business, risk factors and financial condition, as well as Form 4 and related insider transaction reports when available, which detail trades by directors and officers.
Real-time updates from the SEC’s EDGAR system help ensure that new DXR filings are quickly reflected. The AI tools on the platform can highlight key points in lengthy filings, such as descriptions of the BVA product line, regulatory milestones, and information about the company’s Nasdaq listing and corporate structure. This makes it easier for investors and researchers to understand how Daxor’s regulatory disclosures relate to its blood volume analysis business.
Daxor Corporation (DXR) filed a Form 4 on 26-Jun-2025 disclosing that director Caleb DesRosiers received 2,500 non-qualified stock options on 24-Jun-2025. The options carry an exercise price of $9.29 and expire on 24-Jun-2030. Vesting occurs in three installments: 833 options on 24-Jun-2025, 833 on 24-Jun-2026 and 834 on 24-Jun-2027. Following the grant, DesRosiers beneficially owns 2,500 derivative securities directly.
The award is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan. No common-stock purchases or sales were reported, making this a routine compensation-related disclosure rather than a signal of insider sentiment.